Alecensa
What Alecensa is used for
Adjuvant treatment of resected non small cell lung cancer (NSCLC) Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK positive NSCLC at high risk of recurrence (see section 5.1 for selection criteria).Treatment of advanced NSCLCAlecensa as monotherapy is indicated for the first line treatment of adult patients with ALK positive advanced NSCLC.Alecensa as monotherapy is indicated for the treatment of adult patients with ALK positive advanced NSCLC previously treated with crizotinib.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Alecensa
- Active substance
- alectinib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01ED03
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2017
Official information
In the USA
Same active substance: Alecensa
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Alecensa used for?
Adjuvant treatment of resected non small cell lung cancer (NSCLC) Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK positive NSCLC at high risk of recurrence (see section 5.1 for selection criteria).Treatment of advanced NSCLCAlecensa as monotherapy is indicated for the first line treatment of adult patients with ALK positive advanced NSCLC.Alecensa as monotherapy is indicated for the treatment of adult patients with ALK positive advanced NSCLC previously treated with crizotinib.
What is the active substance in Alecensa?
Alecensa contains alectinib.
Who makes Alecensa?
The EU marketing authorisation holder is Roche Registration GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU